Prolia (Denosumab) Side Effects: Rare but Serious Adverse Events

What Makes Denosumab's Side-Effect Profile Unique

Denosumab works by binding RANKL (receptor activator of nuclear factor kappa-B ligand), effectively halting osteoclast formation and activity. That mechanism is powerful, but it also explains why the drug's rare adverse events differ from bisphosphonates in both character and timing. The risks discussed here are infrequent in absolute terms, yet each one requires active screening, patient counseling, and, in some cases, dose-timing adjustments before the event occurs.

How the RANKL Pathway Drives These Risks

Blocking RANKL suppresses bone resorption more completely than oral bisphosphonates, dropping serum calcium and driving the hypocalcemia risk in susceptible patients. Because denosumab does not incorporate into bone matrix the way bisphosphonates do, its effect is fully reversible when the drug is stopped. That reversibility is the direct cause of the rebound fracture risk described later.

Why "Rare" Still Warrants Attention

In the FREEDOM trial (N=7,808), denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared with placebo. [1] Those benefits are real and substantial. The serious adverse events below affect a small minority of patients, but their consequences, including jaw necrosis, femur fracture, and rapid vertebral collapse after stopping therapy, justify structured monitoring protocols for every patient on the drug.

Severe Hypocalcemia

Hypocalcemia is the most medically urgent of denosumab's rare adverse events. The drug suppresses osteoclasts so completely that the normal flux of calcium from bone resorption is sharply reduced, dropping serum calcium in patients who cannot compensate through dietary intake, vitamin D absorption, or parathyroid function.

Who Is at Highest Risk

Patients with pre-existing hypocalcemia, severe renal impairment (creatinine clearance <30 mL/min), hypoparathyroidism, or malabsorption syndromes carry the greatest risk. A 2015 analysis of FDA Adverse Event Reporting System (FAERS) data identified hypoparathyroidism and renal insufficiency as the two strongest independent predictors of clinically significant hypocalcemia on denosumab. [2]

The FDA label for Prolia states that hypocalcemia must be corrected before initiating therapy and that serum calcium should be monitored, especially in the first weeks after each injection. [3] Patients with estimated glomerular filtration rate <30 mL/min who receive denosumab for osteoporosis (not the higher oncology dose) had hypocalcemia rates approaching 3.5% in post-market cohort data.

Clinical Presentation and Management

Symptoms range from perioral tingling and muscle cramps to tetany, seizures, and QT prolongation on ECG. Asymptomatic drops in corrected serum calcium below 8.0 mg/dL still carry cardiac risk and require oral calcium supplementation increases or, in severe cases, IV calcium gluconate.

Standard prevention protocol: 1,000 to 1,200 mg elemental calcium daily plus vitamin D 800 to 1,000 IU daily, begun before the first injection and continued throughout therapy. Patients with vitamin D levels below 30 ng/mL should be repleted before injection day.

Osteonecrosis of the Jaw (ONJ)

ONJ is defined as exposed, necrotic bone in the jaw persisting for more than 8 weeks in the absence of head and neck radiation or metastatic disease. Denosumab at the osteoporosis dose (60 mg every 6 months) carries a meaningfully lower ONJ risk than the oncology dose (120 mg monthly for bone metastases), but the risk is not zero.

Incidence Data from Trials and Post-Market Surveillance

In the long-term FREEDOM extension study, covering up to 10 years of denosumab exposure in 4,550 women, ONJ was confirmed in 13 subjects. That translates to roughly 5.2 cases per 10,000 patient-years, or approximately 0.04% per patient-year. [4] Post-market dental registry data from Europe have reported slightly higher estimates, around 0.07% per patient-year, in populations with higher rates of dental extraction or poor oral hygiene. [5]

Risk factors include invasive dental procedures (especially extractions and implant placement), periodontal disease, poorly fitting dentures, chemotherapy, corticosteroid use, and diabetes.

Dental Management Protocol

The American Association of Oral and Maxillofacial Surgeons recommends that all patients beginning antiresorptive therapy for osteoporosis have a dental evaluation before the first dose if possible. [6] Necessary invasive procedures should be completed, and surgical sites should be healed, before starting denosumab.

For patients already on therapy who need extraction, most guidelines advise against a "drug holiday" at the osteoporosis dose, because the ONJ risk reduction from stopping is unproven and the rebound fracture risk (described below) is real. Consultation between the prescriber and oral surgeon on a case-by-case basis is preferred.

Atypical Femoral Fractures (AFF)

Atypical femoral fractures occur in the subtrochanteric or diaphyseal region of the femur with little or no trauma. They differ from ordinary osteoporotic hip fractures by their transverse orientation, lateral cortical beaking, and bilateral occurrence in a meaningful minority of patients.

Incidence and Duration Dependence

The American Society for Bone and Mineral Research task force reported that AFF incidence with antiresorptive drugs (including denosumab) rises with duration of exposure. [7] In a large Swedish registry of 3,944 patients on denosumab, AFF incidence was approximately 3.2 per 10,000 patient-years in the first 3 years but climbed to an estimated 10 to 12 per 10,000 patient-years beyond 6 years of continuous use. [8]

Patients of Asian descent and those with femoral bowing appear to carry higher anatomical risk.

Prodromal Pain and Radiologic Features

Up to 70% of patients with AFF report prodromal thigh or groin pain for weeks to months before fracture. This pain should prompt bilateral femur X-rays. A lateral cortical stress reaction ("dreaded black line") on imaging warrants urgent orthopedic referral.

Complete ATF requires surgical fixation with an intramedullary nail. Bilateral imaging at the time of diagnosis is standard because contralateral incomplete fractures are found in roughly 28% of cases.

The HealthRX Bone Safety Framework (to be inserted by the editorial team) outlines a structured decision tree for patients on denosumab beyond 5 years, integrating AFF risk, ONJ risk, and rebound fracture risk into a single clinical decision pathway.

Serious Skin Infections

The FDA label for Prolia carries a warning for serious skin infections, including cellulitis requiring hospitalization. Because RANKL is expressed on immune cells as well as osteoclasts, denosumab may modestly impair local skin immune responses.

Trial Data

In the FREEDOM trial (N=7,808), serious skin infections (defined as events requiring hospitalization) occurred in 0.4% of the denosumab group versus 0.1% in the placebo group over 36 months. [1] The absolute risk difference is small at 0.3 percentage points, but it was statistically significant (P<0.01) and prompted the FDA labeling addition.

Cellulitis of the lower extremities was the most common presentation. Patients with eczema, psoriasis, or prior skin infections were disproportionately represented in case reports submitted to FAERS. [3]

Guidance for Patients and Prescribers

Patients should be counseled to report any rapidly spreading skin redness, warmth, or swelling promptly. Denosumab should be used with caution in patients with a history of recurrent cellulitis. Active serious infections are a contraindication to administration until the infection resolves.

Rebound Vertebral Fractures After Discontinuation

This is the adverse event most specific to denosumab and, arguably, the one most underappreciated in clinical practice. When denosumab is stopped without transitioning to another antiresorptive agent, bone turnover rebounds sharply above pre-treatment baseline within 6 to 12 months. In susceptible patients, this rebound causes rapid bone loss and, in the worst cases, multiple simultaneous vertebral fractures.

Incidence and Severity Data

A 2018 case series published in the Journal of Bone and Mineral Research documented multiple vertebral fractures in approximately 2.9% of patients who discontinued denosumab without subsequent antiresorptive therapy. [9] These events occurred at a median of 9 months after the last injection, frequently affecting two or more vertebral levels simultaneously and resulting in height loss, pain, and kyphosis disproportionate to what would be expected from single-level osteoporotic fractures.

The FREEDOM trial extension data showed that patients who discontinued denosumab lost bone mineral density (BMD) rapidly: within 12 months of stopping, spine BMD returned to near pre-treatment levels, and fracture rates in the year after discontinuation exceeded those seen in the placebo arm of the original trial. [4]

A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism (N=1,232 patients across 11 studies) confirmed that discontinuation without bridging therapy was associated with a statistically significant increase in vertebral fracture risk compared with continued therapy (hazard ratio approximately 2.4). [10]

Who Is at Highest Risk for Rebound Fractures

• Patients with prevalent vertebral fractures at baseline
• Those who had significant BMD gains during denosumab therapy (larger gains predict larger rebound loss)
• Patients stopping after fewer than 2 years of treatment, when residual drug effect in bone matrix is minimal
• Women with BMD T-scores that remain below minus 2.5 at the time of discontinuation

Transition Strategy to Prevent Rebound

The Endocrine Society and the American Society for Bone and Mineral Research both emphasize that denosumab should not be discontinued without a transition plan. The most studied approach is a single dose of zoledronic acid 5 mg IV given 6 months after the last denosumab injection, timed to coincide with the rebound window. [11]

A 2021 prospective study (N=61) found that a single infusion of zoledronic acid at the 6-month mark attenuated the BMD rebound by approximately 80% compared with no transition therapy. [12] Oral bisphosphonates are a second-line option in patients who cannot tolerate IV infusion, though their efficacy in blunting the rebound is less well established.

Prescribers should document a transition plan before the patient receives their first denosumab injection, not only when stopping becomes relevant.

Hypersensitivity and Immunogenicity Reactions

Anaphylaxis to denosumab is rare but documented. The FDA label lists hypersensitivity reactions, including urticaria, facial swelling, lip swelling, pharyngeal edema, dyspnea, and anaphylaxis, as potential adverse events. [3] Post-market reports to FAERS through 2023 include 47 confirmed cases of anaphylaxis attributed to denosumab, a rate estimated at fewer than 1 per 100,000 injections in real-world use.

Patients with a known hypersensitivity to any component of the product should not receive denosumab. The drug contains sorbitol as an excipient, and rare hereditary fructose intolerance represents a contraindication. After each injection, patients should remain in the clinic for at least 15 to 20 minutes and be counseled on signs of a delayed reaction.

Drug Interactions That Amplify Serious Risks

Denosumab is a biologic and is not metabolized by cytochrome P450 enzymes, so classic pharmacokinetic drug-drug interactions are uncommon. The clinically meaningful interactions are pharmacodynamic.

Immunosuppressants

Concurrent use of systemic corticosteroids, methotrexate, or biologic immunosuppressants (such as tumor necrosis factor inhibitors) may compound the infection risk identified in FREEDOM. Prescribers managing inflammatory arthritis or inflammatory bowel disease who are considering denosumab for glucocorticoid-induced osteoporosis should weigh this combination carefully.

Other Calcium-Lowering Agents

Loop diuretics, cinacalcet, and aminoglycosides all reduce serum calcium independently. Adding denosumab to any of these agents requires closer calcium monitoring in the first 4 to 6 weeks post-injection.

Antiangiogenic Agents

Bevacizumab and sunitinib, used in oncology, are associated with ONJ independently. Patients receiving these drugs alongside denosumab (usually at the higher oncology dose) carry an ONJ risk that is roughly additive based on FAERS pharmacovigilance data. [2]

Special Populations

Patients With Renal Impairment

Denosumab clearance is not renally mediated, so dose adjustment is not required for renal impairment. However, patients with estimated GFR <30 mL/min have significantly impaired renal calcium conservation, making hypocalcemia the primary safety concern. Serum calcium and phosphorus should be checked at baseline, at 1 to 2 weeks post-injection, and again at 4 weeks in this population.

Pregnant and Breastfeeding Women

Denosumab is contraindicated in pregnancy. Animal studies showed fetal harm at exposures below the clinical dose. Denosumab should be withheld until 5 months after the last dose before attempting conception, given the drug's approximately 26-day serum half-life and expected tissue clearance timeline. [3] Data on breastfeeding transfer are unavailable; most clinicians advise against breastfeeding during therapy.

Patients Over 75 Years

The FREEDOM trial included women up to age 90. The benefit-to-risk profile in this group generally favors treatment because fall-related hip fracture mortality is high. The serious adverse event rates in the over-75 subgroup did not differ significantly from those in the overall population in FREEDOM, though real-world renal impairment is more prevalent in elderly patients, which concentrates the hypocalcemia risk. [1]

Monitoring and Safety Checklist for Prescribers

A structured pre-treatment and on-treatment monitoring approach covers the majority of serious adverse event risk. The following checklist reflects current FDA labeling and Endocrine Society guidance. [3] [11]

Before the first dose:

• Correct pre-existing hypocalcemia
• Measure serum 25-hydroxyvitamin D; replete if below 30 ng/mL
• Complete dental evaluation and heal any open surgical sites
• Document a discontinuation and transition plan in the chart
• Screen for active infection; delay injection if present

After each injection (every 6 months):

• Serum calcium at 1 to 2 weeks for high-risk patients (renal impairment, hypoparathyroidism)
• Ask about thigh or groin pain at every visit (AFF screening)
• Inspect injection site and ask about skin changes
• Review dental health at annual visits

At 3 to 5 years:

• Reassess fracture risk and FRAX score
• Discuss AFF and ONJ risk trajectory with the patient
• Document decision to continue or transition with rationale

What Patients Should Report Immediately

Any of the following warrants a same-day call to the prescriber or an emergency department visit:

• Numbness or tingling around the mouth, fingers, or toes (hypocalcemia)
• Muscle cramps, spasms, or tetany
• Jaw pain, swelling, or exposed bone in the mouth
• Sudden thigh or groin pain, especially after minimal activity
• Spreading skin redness, warmth, or swelling
• Difficulty breathing or throat tightness after injection (anaphylaxis)